Canary in the Coal Mine: PAD (Peripheral Arterial Disease)
Case Presentation
Meet Mr. R.
Mr. R. is a 65-year-old retired electrician. Former smoker — quit 3 years ago after 35 pack-years. Prediabetic with an A1c of 6.1%. Hypertension managed on lisinopril 10 mg. About 10 years ago, his primary care physician started him on simvastatin 20 mg — "just because" he was a smoker with a few risk factors. No prior heart disease. No prior vascular events.
The Visit: Mr. R. starts noticing progressive bilateral calf cramping after walking 2–3 blocks. It gets better when he stops. Classic intermittent claudication. His PCP orders ankle-brachial indices: 0.68 right, 0.72 left. The diagnosis is confirmed — peripheral artery disease.
The Referral: The PCP refers directly to vascular surgery. Does not refer to cardiology. The PCP's note reads: "Hypercholesterolemia: on statin, lipids not bad for primary prevention."
The Problem: His last LDL cholesterol was 120 mg/dL — from routine labs drawn a year ago. He has been on simvastatin 20 mg for a decade. Nobody has rechecked, retitrated, or reconsidered. Because nobody recognized that the moment PAD was diagnosed, this man crossed from "primary prevention" to "secondary prevention — ASCVD confirmed." His LDL-C target just dropped from <100 to <70 mg/dL (ACC/AHA) or <55 mg/dL (ESC/EAS). His simvastatin 20 mg — a low-intensity statin — is now hopelessly inadequate.
The Statin Problem Within the Problem: Let's talk about that simvastatin 20 mg. This isn't just the wrong dose — it's the wrong drug. Simvastatin at 20 mg is a low-intensity statin by ACC/AHA classification, expected to lower LDL-C by less than 30%. It's an outdated molecule with extensive CYP3A4 drug-drug interactions — it interacts with amlodipine (dose-capped to simvastatin 20 mg), amiodarone, diltiazem, verapamil, certain antibiotics, and grapefruit juice. Its interaction profile makes it a minefield in the typical older patient on multiple medications. In the current era of atorvastatin and rosuvastatin — both available as inexpensive generics, both offering high-intensity options with cleaner interaction profiles — simvastatin has essentially no role in modern lipid management. The only conceivable exception would be the rare patient who truly cannot tolerate any other statin, which would be unusual and clinically peculiar. Mr. R. wasn't on simvastatin because it was the best choice. He was on it because it was started a decade ago and nobody ever revisited it. That's inertia, not medicine.
The Vascular Surgeon: Sees the patient. Orders CTA. Does a femoral-popliteal angioplasty. Note reads: "On statin, managed by PCP." Sends the patient home. No lipid recheck. No high-intensity statin. No antiplatelet optimization. No screening for coronary or carotid disease.
The PCP: Gets the post-op note. Assumes the vascular surgeon "handled it." Continues simvastatin 20 mg. Nobody screens for coronary artery disease. Nobody checks carotid arteries. Nobody starts aspirin plus low-dose rivaroxaban. Nobody considers PCSK9 inhibitor eligibility.
The Patient: Falls through every crack in the system. He has confirmed atherosclerotic cardiovascular disease with a mortality risk exceeding isolated coronary artery disease — and he's being managed as a primary prevention patient on a low-intensity statin that hasn't been touched in a decade.
The canary sang. Nobody evacuated the mine.
Flying Under the Radar
Peripheral artery disease is the canary in the coal mine of cardiovascular medicine. It announces — loudly — that systemic atherosclerosis is present. But unlike the canary in the actual coal mine, whose death prompted immediate evacuation, PAD's alarm is routinely ignored. The diagnosis is made. The procedure is done. And nobody evacuates. Nobody treats the disease. Nobody owns the patient.
This is the story of the most neglected diagnosis in cardiovascular medicine — a disease where the REACH Registry documented the highest mortality and CV event rates of any ASCVD subgroup, yet patients consistently receive the least aggressive treatment.
The Referral Pattern That Kills
| Specialty Referred To | % of PAD Referrals | Manages Disease? |
|---|---|---|
| Vascular Surgeons | 49% | No — fixes anatomy |
| General Surgeons | 33% | No |
| Cardiothoracic Surgeons | 13% | No |
| Cardiologists | 4% | Yes |
| Radiologists | 1% | No |
The specialty best equipped to manage the systemic disease that PAD represents — cardiology — sees only 4% of these patients. Meanwhile, 86% of internists simply order diagnostic tests rather than referring to any specialist at all, managing PAD in isolation without reclassifying the patient to secondary prevention.
The Specialty Lineage Problem
Cardiology, endocrinology, nephrology — these specialties were spawned from internal medicine. They were trained to think about the disease and its risk factors, not just the anatomy. Vascular surgery was spawned from general surgery. They were trained to fix the pipe. Open the vessel, bypass it, reroute it. Move on. This is not a criticism of individual vascular surgeons — it's a structural problem in training and scope. The result: vascular surgeons address the symptom (claudication, critical limb ischemia) but not the disease (systemic atherosclerosis).
The Self-Reinforcing Blindness
Only 4% of PAD patients are referred to cardiology. That's not just a failure — it's a self-perpetuating one. Because cardiology rarely gets PAD referrals, cardiologists rarely see PAD patients. They never develop expertise, awareness, or urgency around PAD. They never advocate for PAD referrals. The referral pattern doesn't change. The blindness persists. If cardiologists actually got the referrals, they'd treat PAD aggressively — just like they treat post-MI patients, post-stroke patients, and every other ASCVD presentation they encounter. Cardiologists know how to optimize secondary prevention. They just never get the chance with PAD.
The Self-Criticism
Even CardioAdvocate — a website built explicitly to close the implementation gap in preventive cardiology — is only now getting around to writing about PAD. If even we deprioritized it, that tells you something about how deeply the neglect runs. Our Brain Attack (Stroke) article was written months ago. Coronary disease has multiple articles. PAD has been on "the list." The canary has been singing in our own mine.
CardioAdvocate™ Checklist — What Every PAD Patient Should Know
1. Understand What PAD Means
2. Verify Your Statin Therapy
3. Confirm Proper Referrals
4. Optimize Antithrombotic Therapy
5. Address the Whole Patient
Questions to Ask Your Clinician
Deep Dive
This is a living section — content will be updated as new evidence emerges, new guidelines are published, and new treatments become available.
1. The Numbers — A Disease Hidden in Plain Sight
Peripheral artery disease is estimated to affect 10 to 12 million Americans aged 40 and older, according to the 2024 ACC/AHA PAD Guideline. Globally, more than 230 million people are affected, based on epidemiological estimates — and the number continues to rise. Earlier NHANES data (1999–2004) using ankle-brachial index screening found a prevalence of approximately 4.3% in U.S. adults over 40, but this likely underestimates the true burden due to the high rate of asymptomatic disease.
Yet the vast majority of these patients are never diagnosed. Classic intermittent claudication — the textbook presentation of calf pain with walking that resolves with rest — is present in only 10–30% of PAD patients. Roughly half are asymptomatic or have atypical symptoms. An estimated 66% of U.S. adults with a low ABI are undiagnosed. The USPSTF has concluded there is insufficient evidence to recommend routine ABI screening in asymptomatic adults — a position that, while evidence-based, perpetuates the cycle of missed diagnoses.
Mortality — The Shocking Reality
PAD carries a mortality risk that surprises even experienced clinicians:
- PAD patients have a hazard ratio of 2.95 for all-cause mortality compared to patients with coronary artery disease (p<0.0001)
- 19 deaths per 100 person-years with PAD events vs. 5 per 100 without
- 70% increased risk of subsequent cardiovascular events after PAD identification
- 80% increased risk of death after symptomatic PAD
- Post-amputation 5-year mortality: 18–60% — higher than most cancers
- Among patients with diabetes and PAD requiring amputation, 5-year mortality reaches 58.8%
REACH Registry: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. Bhatt DL, et al. JAMA. 2006;295:180-189. — 67,888 patients across CAD, stroke, and PAD — PAD patients had the highest annual mortality and CV event rates of any ASCVD subgroup.
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for Management of Lower Extremity PAD. J Am Coll Cardiol. 2024.
The paradox is devastating: PAD patients carry the highest cardiovascular risk among all ASCVD populations — yet receive the least aggressive treatment.
2. The Treatment Gap — Everyone Failed This Patient
| Medication Class | PAD Patients Receiving | Adequacy |
|---|---|---|
| High-intensity statin | 13.6% | Abysmal |
| Any statin (without concurrent CVD) | 18.3% | Terrible |
| Any antiplatelet | 35.8% | Terrible |
| Any antiplatelet (without concurrent CVD) | 27.4% | Terrible |
| ACE inhibitor or ARB | 24.9% | Poor |
| ZERO secondary prevention meds (no concurrent CVD) | 53.7% | Catastrophic |
Let that last row sink in: more than half of PAD patients without a concurrent coronary or cerebrovascular diagnosis are on absolutely no secondary prevention therapies. They have confirmed atherosclerotic cardiovascular disease, and they are receiving nothing.
PAD patients are less than half as likely to be on high-intensity statins compared to CAD patients, despite the fact that high-intensity statin therapy in PAD is associated with a 26% mortality reduction and 33% amputation risk reduction.
At the time of vascular referral, only 35% of patients are on best medical therapy. But patients with a prior heart disease diagnosis are 7 times more likely to be receiving appropriate medications. This single statistic encapsulates the entire problem: if you've already been "claimed" by cardiology, you get treated. If PAD is your presenting ASCVD, you don't.
3. The Evidence Paradox — Well-Studied, Under-Treated
PAD is not an evidence desert. It's one of the best-represented conditions in cardiovascular trial history. The irony is that the data proving these patients benefit enormously from treatment has existed for decades — and been ignored.
| Trial | Year | Agent | PAD Patients | Key PAD Finding |
|---|---|---|---|---|
| 4S | 1994 | Simvastatin | ~6% with IC | 38% reduction in new/worsening claudication |
| HPS | 2002 | Simvastatin 40 mg | 6,748 PAD | 22% reduction major vascular events; ARR 63 vs 50 per 1,000 in non-PAD |
| SPARCL | 2006 | Atorvastatin | PAD tracked | 43% fewer peripheral events vs placebo |
| IMPROVE-IT | 2015 | Ezetimibe + statin | 5.5% PAD | Largest absolute MACE reduction in PAD subgroup |
| FOURIER (PAD) | 2017 | Evolocumab | 13.2% PAD | HR 0.73 PAD vs 0.81 non-PAD; 42% reduction in MALE; ARR 3.5% vs 1.6% |
| ODYSSEY | 2018 | Alirocumab | 4% PAD | 31% reduction PAD events; linked to Lp(a) reduction |
The key finding across all of these trials: PAD patients consistently show greater relative AND absolute risk reduction from aggressive lipid lowering compared to CAD-only patients — yet receive less of it.
- FOURIER PAD subgroup: 3.5% absolute reduction in PAD vs 1.6% in non-PAD
- HPS: 63 per 1,000 absolute risk reduction in PAD vs 50 per 1,000 in non-PAD
- FOURIER: 42% reduction in major adverse limb events (MALE) with evolocumab
4. The Pharmacotherapy History — Tools We Have but Don't Use
One of the earliest drugs marketed for PAD, pentoxifylline was a rheologic agent meant to improve blood flow. The Cochrane systematic review concluded it is "uncertain whether pentoxifylline works better than placebo." It has been removed from European guidelines and is effectively obsolete.
A PDE III inhibitor with antiplatelet and vasodilatory properties, cilostazol is the only drug proven to consistently improve walking distance in claudication. It carries an ACC/AHA Class I recommendation for claudication symptom relief.
But 45% of physicians have no intention to prescribe it. It is contraindicated in any degree of heart failure. It was dropped from ESC/ESVS guidelines in 2017. And critically, it treats the symptom, not the disease. Making someone walk farther without treating the underlying atherosclerosis is like silencing the smoke alarm without putting out the fire.
First-in-class PAR-1 (protease-activated receptor-1) antagonist — a novel antiplatelet mechanism that selectively blocks thrombin's activation of platelets. The TRA 2P-TIMI 50 trial enrolled 5,845 PAD patients and found remarkable results:
- 15% reduction in MACE (HR 0.85, p=0.034)
- 30% reduction in major adverse limb events (HR 0.70, p=0.011)
- Greater than 55% reduction in peripheral revascularization for claudication
Why it was abandoned: Intracranial hemorrhage increased 5-fold (1.1% vs 0.2%, p<0.001). Black box warning. Contraindicated in prior stroke, TIA, or intracranial hemorrhage. Since PAD patients frequently have coexisting cerebrovascular disease, this effectively eliminated most of the target population.
The tragedy: For PAD patients without cerebrovascular disease, the limb outcomes were excellent. This was a genuinely good drug for a specific population — killed by a safety signal in a different population. Vorapaxar worked. It was a victim of its own broad enrollment strategy.
COMPASS Trial (2017): The landmark COMPASS trial enrolled 4,129 PAD patients and tested rivaroxaban 2.5 mg BID plus aspirin versus aspirin alone:
- 28% reduction in MACE
- 31% reduction in MACE + MALE (including major amputation)
- High-risk PAD subgroups: up to 22.6% event rates at 30 months — massive absolute benefit
- Major bleeding: 2.0% absolute increase; fatal/critical organ bleeding only 0.4%
- Net clinical benefit: 3.2% absolute risk reduction
VOYAGER PAD (2021): The VOYAGER PAD trial extended the evidence to PAD patients after revascularization — rivaroxaban plus aspirin was superior for acute limb ischemia, amputation, MI, stroke, and CV death. Benefit was seen in both surgical and endovascular revascularization with no significant increase in severe bleeding.
5. Antiplatelet Therapy in PAD — A Complicated Landscape
The CAPRIE trial (1996) established clopidogrel as modestly superior to aspirin for ASCVD patients — but the PAD subgroup showed the strongest benefit of all three vascular beds, with a 23.8% relative risk reduction versus aspirin. This subgroup finding contributed to the guideline preference for clopidogrel over aspirin in symptomatic PAD.
Today, the 2024 ACC/AHA PAD Guideline recommends single antiplatelet therapy (aspirin or clopidogrel) for symptomatic PAD, and the dual pathway approach (rivaroxaban 2.5 mg BID + aspirin) for patients at high risk of ischemic events without high bleeding risk. But these recommendations still reach only a fraction of eligible patients.
6. The Emerging Landscape
SGLT2 Inhibitors in PAD
Initial concern arose from the CANVAS trial, which reported a 2-fold increase in amputation risk with canagliflozin (FDA black box warning). Real-world data now suggests this may have been overstated, and SGLT2 inhibitors may improve endothelial function and lower heart failure hospitalization in PAD patients. Their role in PAD patients with diabetes appears to be one of cardiovascular and renal protection with careful monitoring.
GLP-1 Receptor Agonists
Emerging data suggests GLP-1 RAs may reduce revascularization needs in PAD through anti-inflammatory and endothelial benefits beyond glycemic control. The SELECT trial demonstrated CV risk reduction in obese patients regardless of diabetes status, positioning GLP-1 RAs as a natural complement to aggressive lipid lowering and antithrombotic therapy across the cardiometabolic spectrum.
Lp(a)-Lowering Agents
The ODYSSEY OUTCOMES trial showed that PAD event reduction was directly linked to Lp(a) reduction with alirocumab. With pelacarsen, olpasiran, and lepodisiran in development — and the Lp(a)HORIZON trial underway — PAD patients with elevated Lp(a) may have an additional therapeutic layer on the horizon. Cross-reference: Little Napoleon Complex — Lipoprotein(a).
7. What Should Have Happened for Mr. R.
Here is the ideal management pathway — the one Mr. R. deserved but didn't receive:
- PCP diagnoses PAD → immediately recognizes this as confirmed ASCVD → reclassifies from primary to secondary prevention
- Switches simvastatin 20 mg to high-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) — there is no reason to keep an outdated statin in a confirmed ASCVD patient
- Checks LDL-C in 4–6 weeks; target now <70 mg/dL (ACC/AHA) or <55 mg/dL (ESC)
- Refers to cardiology for: coronary disease screening, carotid duplex, comprehensive ASCVD risk management
- Also refers to vascular surgery for revascularization assessment — surgery addresses the symptom; cardiology manages the disease
- Starts low-dose rivaroxaban 2.5 mg BID + aspirin (COMPASS regimen) — or at minimum ensures appropriate antiplatelet therapy
- Aggressive BP control (target <130/80)
- Prediabetes management: lifestyle intervention, weight management, metabolic monitoring — recognizing that prediabetes + PAD = very high cardiometabolic risk
- Supervised exercise program referral — proven to improve claudication as effectively as many interventions
- Smoking cessation reinforcement and pharmacotherapy support
Phenotype Cross-Links
Sister article — same ASCVD orphan problem, same ownership vacuum, same secondary prevention failure. PAD and stroke are two sides of the same coin.
ODYSSEY OUTCOMES linked PAD event reduction directly to Lp(a) lowering. Elevated Lp(a) may be an underrecognized driver of PAD progression.
Blood pressure optimization in PAD; target <130/80. Hypertension accelerates all forms of atherosclerosis.
The prediabetes-to-PAD continuum. Metabolic syndrome overlap amplifies cardiometabolic risk.
Metabolic drivers of atherosclerosis; GLP-1 RA cardiovascular benefits across the cardiometabolic spectrum.
Heart failure as cilostazol contraindication; SGLT2i dual benefit in HFpEF and vascular protection.
Anticoagulation overlap; rivaroxaban use in PAD patients with concurrent AFib.
The Bottom Line
- PAD is atherosclerotic cardiovascular disease — the same disease that causes heart attacks and strokes
- PAD patients carry higher mortality than those with coronary artery disease alone — yet receive far less aggressive treatment
- The ownership vacuum — between vascular surgery, primary care, and cardiology — leaves most PAD patients undertreated or completely untreated
- High-intensity statin therapy, proper antiplatelet/antithrombotic therapy, and aggressive risk factor management are proven to reduce events and save limbs
- Simvastatin has no meaningful role in modern secondary prevention — if your patient is on simvastatin for ASCVD, it's time to switch
- Low-dose rivaroxaban + aspirin (COMPASS/VOYAGER PAD) reduces events by 28–31% — and almost nobody prescribes it
- Only 4% of PAD patients see a cardiologist. That must change.
The canary sang. It's time to evacuate the mine.
